|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We also found suggestive associations in women for GAD1, GRIA3, and BDNF with depression accompanied by fatigue, and for CRHR1 with depression accompanied by early morning awakenings.
|
19548263 |
2010 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A binary logistic regression analyses were conducted to test the association between all four ratings in GAD-7 (anxiety) and PHQ-9 (depression) scales subitems as covariates, and migraine vs no headache as the outcome.
|
28324317 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in DEMS correlated with changes in both PHQ-8 and GAD-7 in the subgroup of patients without prior depression or anxiety diagnosis (ρ = 0.6, P = 0.002; ρ = 0.4, P = 0.02).
|
30950896 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depression was more commonly studied (ranged from 1%-30%).Prevalence of GAD ranged from 1%-26%.
|
29966886 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial.
|
28242498 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The resulting groups were characterized with regard to Quality of Life (MacNew), anxiety and depression (GAD-7 and PHQ-9) and resilience (RS-13).
|
28006984 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
PSYGENET |
As a consequence broader entities such as depression-GAD spectrum, panic-phobias spectrum and OCD spectrum including eating disorders and pathological gambling are taken into consideration; (c) Diagnostic categories use thresholds to delimitate a border with normals.This creates "subthreshold" conditions.
|
18344044 |
2008 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like.
|
25106036 |
2014 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> The study indicated that past-year Wave II financial mistreatment was associated with significantly increased likelihood of depression, PTSD, GAD, and poor self-rated health; and financial mistreatment perpetrated by family members was associated with particularly increased risk of depression.
|
29665715 |
2019 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with PNES had higher self-reported anxiety and depression levels (GAD-7: p = 0.04, PHQ-9: p < 0.01; BDI-II: p < 0.01) but similar QOL to PWE (p = 0.78).
|
31759316 |
2020 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females.
|
22662185 |
2012 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas cortical GAD67 reduction and subsequent GABA level decrease are consistently observed in schizophrenia and depression, it remains unclear how these GABAergic abnormalities contribute to specific symptoms.
|
29362511 |
2018 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Primary outcomes included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.
|
28057609 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The response rate, as measured by a 50% decrease in scores, for those with initial scores ≥10 was 58.6% for depression (PHQ-9) and 50% for anxiety (GAD-7).
|
28165775 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, self-rating questionnaires were used to assess somatic symptom severity (PHQ-15), depression severity (PHQ-9) and anxiety severity (GAD-7).
|
28554368 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the third trimester, a second FOBS score, and saliva sample were collected, and the Personal Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) were administered to measure depression and anxiety respectively.
|
31306998 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; <i>P</i>=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; <i>P</i>=0.91).
|
29025788 |
2017 |